AI Article Synopsis
- * The study aimed to evaluate the impact of this high-dose progestogen treatment on both endometriosis and breast health using breast ultrasounds before and after the treatment period.
- * Results showed a significant reduction in the size of the mammary gland and improvement in mastopathy, while duct diameter showed a slight decrease and fatty tissue increase but were not statistically significant.
Article Abstract
In a clinical pilot study, 21 women with endometriosis have been primarely treated with dienogest 2 x 10 mg daily p.o. for 24 weeks. Besides the effect on endometriosis the action of such high-dose progestogen treatment on the breast was evaluated by breast ultrasound prior to medication and at 24 weeks of medical treatment. In all women, a significant size reduction of the mammary gland (p < 0.023) and regression of mastopathic changes were observed. There was a non-significant reduction (p = 0.089) of the maximum diameter of the ducts. The portion of the fatty tissue increased slightly, but not significantly (p = 0.348).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09513590902836536 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!